Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4203)
All Articles published online
|
Feb 28, 2005 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ceni E, Mello T, Tarocchi M, Crabb DW, Caldini A, Invernizzi P, Surrenti C, Milani S, Galli A. Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. World J Gastroenterol 2005; 11(8): 1122-1130 [PMID: 15754392 DOI: 10.3748/wjg.v11.i8.1122] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i8/1122.htm |
| Number | Citing Articles |
| 1 |
Tommaso Mello, Maria Materozzi, Andrea Galli. PPARs and Mitochondrial Metabolism: From NAFLD to HCC. PPAR Research 2016; 2016: 1 doi: 10.1155/2016/7403230
|
| 2 |
Miguel Hernandez-Quiles, Marjoleine F. Broekema, Eric Kalkhoven. PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.624112
|
| 3 |
Simone Polvani, Mirko Tarocchi, Sara Tempesti, Andrea Galli. Nuclear receptors and pathogenesis of pancreatic cancer. World Journal of Gastroenterology 2014; 20(34): 12062-12081 doi: 10.3748/wjg.v20.i34.12062
|
| 4 |
Yan-Ming Zhou, Yin-Hao Wen, Xiao-Yan Kang, Hai-Hua Qian, Jia-Mei Yang, Zheng-Feng Yin. Troglitazone, a peroxisome proliferator-activated receptor γ ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World Journal of Gastroenterology 2008; 14(14): 2168-2173 doi: 10.3748/wjg.14.2168
|
| 5 |
Cindy K. Pon, Sue M. Firth, Robert C. Baxter. Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth. Molecular and Cellular Endocrinology 2015; 399: 354 doi: 10.1016/j.mce.2014.10.023
|
| 6 |
Simone Polvani, Mirko Tarocchi, Sara Tempesti, Lapo Bencini, Andrea Galli. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World Journal of Gastroenterology 2016; 22(8): 2441-2459 doi: 10.3748/wjg.v22.i8.2441
|
| 7 |
Alessandra Dicitore, Michele Caraglia, Germano Gaudenzi, Gloria Manfredi, Bruno Amato, Daniela Mari, Luca Persani, Claudio Arra, Giovanni Vitale. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): At the cross-road of pancreatic cancer cell proliferation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2014; 1845(1): 42 doi: 10.1016/j.bbcan.2013.11.003
|
| 8 |
Přemysl Frič, Jan Škrha, Aleksi Šedo, Petr Bušek, Klára Kmochová, Martin Laclav, Svatopluk Solař, Bohuš Bunganič, Miroslav Zavoral. Early pancreatic carcinogenesis – risk factors, early symptoms, and the impact of antidiabetic drugs. European Journal of Gastroenterology & Hepatology 2016; 28(7): e19 doi: 10.1097/MEG.0000000000000646
|
| 9 |
Shanshan Song, Baosheng Wang, Xin Zhang, Liliang Hao, Xianliang Hu, Zhongxiang Li, Shaolong Sun, Olaf M. Dekkers. Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer: A Meta-Analysis. PLOS ONE 2015; 10(7): e0134321 doi: 10.1371/journal.pone.0134321
|
| 10 |
Andrea Galli, Tommaso Mello, Elisabetta Ceni, Elisabetta Surrenti, Calogero Surrenti. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opinion on Investigational Drugs 2006; 15(9): 1039 doi: 10.1517/13543784.15.9.1039
|
| 11 |
Simone Polvani, Mirko Tarocchi, Sara Tempesti, Tommaso Mello, Elisabetta Ceni, Francesca Buccoliero, Massimo D'Amico, Vieri Boddi, Marco Farsi, Silvia Nesi, Gabriella Nesi, Stefano Milani, Andrea Galli. COUP‐TFII in pancreatic adenocarcinoma: Clinical implication for patient survival and tumor progression. International Journal of Cancer 2014; 134(7): 1648 doi: 10.1002/ijc.28502
|
| 12 |
Athina Stravodimou, Gianluigi Mazzoccoli, Ioannis A. Voutsadakis. Peroxisome Proliferator-Activated Receptor Gamma and Regulations by the Ubiquitin-Proteasome System in Pancreatic Cancer. PPAR Research 2012; 2012: 1 doi: 10.1155/2012/367450
|
| 13 |
Carol Koro, Steven Barrett, Nawab Qizilbash. Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents. Pharmacoepidemiology and Drug Safety 2007; 16(5): 485 doi: 10.1002/pds.1352
|
| 14 |
Thomas E. Adrian, Rene Hennig, Helmut Friess, Xianzhong Ding, Dipak Panigrahy. The Role of PPARγ Receptors and Leukotriene B4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Research 2008; 2008(1) doi: 10.1155/2008/827096
|
| 15 |
Roberta Noè, Alessandro Carrer. Diet predisposes to pancreatic cancer through cellular nutrient sensing pathways. FEBS Letters 2024; 598(20): 2470 doi: 10.1002/1873-3468.14959
|
| 16 |
Andrea Galli, Elisabetta Ceni, Tommaso Mello, Simone Polvani, Mirko Tarocchi, Francesca Buccoliero, Francesca Lisi, Laura Cioni, Barbara Ottanelli, Valeria Foresta, Guido Mastrobuoni, Gloriano Moneti, Giuseppe Pieraccini, Calogero Surrenti, Stefano Milani. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus–transgenic mice by peroxisome proliferator‐activated receptor γ–independent regulation of nucleophosmin†. Hepatology 2010; 52(2): 493 doi: 10.1002/hep.23669
|
| 17 |
Guido Eibl, Dipak Panigrahy. The Role of PPAR‐γ and Its Interaction with COX‐2 in Pancreatic Cancer. PPAR Research 2008; 2008(1) doi: 10.1155/2008/326915
|